GHRP-2 dosage: chart, reported range and vial math

How to mix a GHRP-2 vial

These steps are for the 5 mg vial picked in the chart. Change the size there and the amounts here change with it.

1. Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
2. Draw 3 mL of bacteriostatic water into a syringe.
3. Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
4. Swirl the vial gently until the powder is gone. Do not shake it.
5. Write the date and 1.6667 mg/mL on the vial, then put it in the fridge.

What GHRP-2 is

GHRP-2 (pralmorelin) is a synthetic six amino acid peptide that makes the pituitary release growth hormone. It acts like ghrelin at the growth hormone secretagogue receptor. [3]

Other names: pralmorelin, growth hormone-releasing peptide-2, growth hormone releasing peptide-2, GH-releasing peptide-2, GHRP 2, GHRP2, KP-102, GPA 748.

How it has been given to people: injection into a vein as a single test dose, continuous infusion under the skin, and nasal spray in human studies.

What to know before reading a dose

• No approved product exists in the US or Canada. GHRP-2 offered for sale is not an approved drug.
• The 100 to 300 mcg range is reported use, not a label dose. No published human study of repeated injections under the skin at those doses was found.
• The one fixed dose with solid human data is a single 100 mcg dose into a vein, used as a test of pituitary function, not as a treatment [1].
• FDA lists GHRP-2 for injectable and nasal use among bulk substances that may present significant safety risks, citing possible immune reactions from aggregation and peptide impurities [12].
• It raises appetite: men ate about 36% more during an infusion [6].
• It is not specific to growth hormone. Prolactin, ACTH and cortisol also rise [8].
• WADA Prohibited List 2026, section [2].2.4, names GHRP-2 (pralmorelin) among GH-releasing peptides; the class is prohibited at all times [17].

Doses on record for GHRP-2

Every dose below was given in a human study or printed on an approved label, and each links to its source. Doses set by body weight are left that way.

What the evidence shows

Each finding is tagged by the kind of study it comes from. Human trials are listed first.

Side effects and warnings

Reported in human studies or on a label:

• GHRP-2 is not specific to growth hormone: doses into a vein also raised prolactin, ACTH and cortisol in healthy adults. [8]
• It raises appetite. In 19 subjects, food intake went up by about 10% at the low infusion rate and about 34% at the high rate. [7]
• In the 30-day infusion study in older adults, safety screening tests stayed normal. [5]
• In children the nasal spray was described as well tolerated. [3]
• FDA says it is aware of reports of serious adverse events in people who received GHRP-2, with cause not established. [12]

GHRP-2 has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.

Storage

Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.

GHRP-2 dosage questions

Sources

Each one was opened on 10 Oct 2026 and matched to the line it supports.

1. Chihara K et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol 2007. PubMed 17609397.
2. Pihoker C et al. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab 1998. PubMed 9543135.
3. Pihoker C et al. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol 1997. PubMed 9390009.
4. Pihoker C et al. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. J Clin Endocrinol Metab 1995. PubMed 7559885.
5. Bowers CY et al. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab 2004. PubMed 15126555.
6. Laferrere B et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 2005. PubMed 15699539.
7. Laferrere B et al. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring) 2006. PubMed 16861611.
8. Arvat E et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997. PubMed 9285939.
9. Bowers CY et al. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine 2001. PubMed 11322505.
10. No authors listed Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D 2004. PubMed 15230633.
11. Fukuda I et al. Adult growth hormone deficiency: current concepts. Neurol Med Chir (Tokyo) 2014. PubMed 25070016.
12. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) US Food and Drug Administration. fda.gov.
13. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act US Food and Drug Administration 2026-05-14. fda.gov.
14. Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks Health Canada 2025-08-01. recalls-rappels.canada.ca.
15. Health Canada Drug Product Database: active ingredient search for pralmorelin (0 records) Health Canada. health-products.canada.ca.
16. Drugs@FDA via openFDA: active ingredient search for pralmorelin (no match) US Food and Drug Administration. api.fda.gov.
17. The Prohibited List (2026 list as shown on the WADA website) World Anti-Doping Agency. wada-ama.org.
18. ClinicalTrials.gov intervention search for GHRP-2 (0 studies) clinicaltrials.gov.

Looked for and not found

• Any published human study of repeated injections under the skin at 100 to 300 mcg. The studies found gave single doses into a vein, a continuous infusion under the skin, a single 10 mcg/kg dose under the skin, or a nasal spray.
• A regulator record for the Japanese diagnostic product. A 2004 drug profile says pralmorelin was awaiting approval in Japan as a diagnostic agent [10] and a 2014 review says the GHRP-2 test is available in Japan [11]; the Japanese label was not opened, so no product is listed.
• Human half-life after injection under the skin. The 0.55 hour figure is from a dose into a vein in children [2].
• A registered trial on ClinicalTrials.gov: intervention searches for GHRP-2 and pralmorelin returned 0 studies on 2026-10-11 [18].
• Any FDA approval or Health Canada authorization, past or present [15], [16].
• Controlled data on body composition, muscle or fat loss in adults. None was found.
• The details behind the adverse event reports that FDA mentions [12]. The page gives no numbers or citations.

Change log

Related

Ipamorelin dosageCJC-1295 without DAC dosageCJC-1295 with DAC dosageSermorelin dosageTesamorelin dosage5 mg vialWhat GHRP-2 isGrowth hormonePeptide dosage chartDosage calculator

DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.